AU2016340098B2 - Combination therapy for treating malignancies - Google Patents

Combination therapy for treating malignancies Download PDF

Info

Publication number
AU2016340098B2
AU2016340098B2 AU2016340098A AU2016340098A AU2016340098B2 AU 2016340098 B2 AU2016340098 B2 AU 2016340098B2 AU 2016340098 A AU2016340098 A AU 2016340098A AU 2016340098 A AU2016340098 A AU 2016340098A AU 2016340098 B2 AU2016340098 B2 AU 2016340098B2
Authority
AU
Australia
Prior art keywords
azacitidine
compound
day
idh2
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016340098A
Other languages
English (en)
Other versions
AU2016340098A1 (en
Inventor
Samuel V. Agresta
Vivek Saroj Kumar Chopra
Jorge Dimartino
Laurie A. Kenvin
Robert Douglas Knight
Kyle Macbeth
Krishnan VISWANADHAN
Qiang Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Celgene Corp
Original Assignee
Laboratoires Servier SAS
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS, Celgene Corp filed Critical Laboratoires Servier SAS
Publication of AU2016340098A1 publication Critical patent/AU2016340098A1/en
Assigned to LES LABORATORIES SERVIER, CELGENE CORPORATION reassignment LES LABORATORIES SERVIER Request for Assignment Assignors: AGIOS PHARMACEUTICALS, INC., CELGENE CORPORATION
Application granted granted Critical
Publication of AU2016340098B2 publication Critical patent/AU2016340098B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016340098A 2015-10-15 2016-10-14 Combination therapy for treating malignancies Active AU2016340098B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562242218P 2015-10-15 2015-10-15
US62/242,218 2015-10-15
PCT/US2016/057102 WO2017066611A1 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies

Publications (2)

Publication Number Publication Date
AU2016340098A1 AU2016340098A1 (en) 2018-05-10
AU2016340098B2 true AU2016340098B2 (en) 2022-06-02

Family

ID=57219007

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016340098A Active AU2016340098B2 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies

Country Status (16)

Country Link
US (2) US10695352B2 (enExample)
EP (1) EP3362070B1 (enExample)
JP (1) JP6895956B2 (enExample)
KR (1) KR102701893B1 (enExample)
CN (1) CN108601787B (enExample)
AU (1) AU2016340098B2 (enExample)
BR (1) BR112018007447B1 (enExample)
CA (1) CA3002029A1 (enExample)
CL (1) CL2018000955A1 (enExample)
EA (1) EA036129B1 (enExample)
ES (1) ES2862730T3 (enExample)
IL (1) IL258580B (enExample)
MX (1) MX381582B (enExample)
SG (2) SG11201802964QA (enExample)
WO (1) WO2017066611A1 (enExample)
ZA (1) ZA201802420B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206601B2 (en) 2013-12-09 2019-02-19 Medtronic, Inc. Noninvasive cardiac therapy evaluation
KR102400737B1 (ko) 2014-03-14 2022-05-20 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
CN108366980A (zh) 2015-10-15 2018-08-03 安吉奥斯医药品有限公司 用于治疗恶性肿瘤的组合疗法
EP3362066B1 (en) * 2015-10-15 2021-10-06 Les Laboratoires Servier SAS Combination therapy for treating malignancies
SG10202111439SA (en) 2015-10-15 2021-11-29 Les Laboratoires Servier Sas Combination therapy for treating malignancies
US11219769B2 (en) 2016-02-26 2022-01-11 Medtronic, Inc. Noninvasive methods and systems of determining the extent of tissue capture from cardiac pacing
CA3036053A1 (en) 2016-09-07 2018-03-15 Celgene Corporation Tablet compositions
US11229653B2 (en) 2017-05-05 2022-01-25 Celgene Corporation Methods of treatment of myeloproliferative neoplasm
JP7263669B2 (ja) * 2017-06-12 2023-04-25 レ ラボラトワール セルヴィエ 併用療法を用いて脳腫瘍を処置する方法
CA3069558A1 (en) * 2017-07-09 2019-01-17 Biosight Ltd. Combination cancer therapy
US11285312B2 (en) 2018-03-29 2022-03-29 Medtronic, Inc. Left ventricular assist device adjustment and evaluation
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
US11697025B2 (en) 2019-03-29 2023-07-11 Medtronic, Inc. Cardiac conduction system capture
CA3137454A1 (en) * 2019-04-29 2020-11-05 Immunogen, Inc. Therapeutic combinations comprising anti-cd123 immunoconjugates
US12447171B2 (en) 2019-06-20 2025-10-21 Celgene Quanticel Research, Inc. Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
US11497431B2 (en) 2019-10-09 2022-11-15 Medtronic, Inc. Systems and methods for configuring cardiac therapy
US12201843B2 (en) 2019-10-09 2025-01-21 Medtronic, Inc. Synchronizing external electrical activity
CN115243690A (zh) 2019-11-14 2022-10-25 新基公司 用于治疗癌症的儿科制剂
CN111087408B (zh) * 2020-01-03 2021-04-02 浙江大学 一种大环结构的idh2突变体抑制剂及其医药用途
WO2022192621A1 (en) * 2021-03-12 2022-09-15 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017821A2 (en) * 2013-08-02 2015-02-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
PT998271E (pt) 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
HUE059635T2 (hu) * 2008-05-15 2022-12-28 Celgene Corp Citidin-analógokat tartalmazó orális készítmények, és eljárások azok alkalmazására
JP6006938B2 (ja) * 2008-06-09 2016-10-12 サイクラセル リミテッド スパシタビン（ｃｎｄａｃ）と、デシタビン及びプロカイン等のｄｎａメチルトランスフェラーゼ阻害剤との組合せ
CA2755394C (en) 2009-03-13 2021-10-19 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
ES2812537T3 (es) * 2009-10-21 2021-03-17 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular
CA2854461C (en) * 2011-11-03 2021-01-19 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and hypomethylating agent
AU2013207289B2 (en) 2012-01-06 2017-09-21 Les Laboratoires Servier Therapeutically active compounds and their methods of use
KR102302091B1 (ko) 2013-07-11 2021-09-16 아지오스 파마슈티컬스 아이엔씨. 암 치료용의 ｉｄｈ２ 돌연변이체 억제제로서의 ｎ,６-비스(아릴 또는 헤테로아릴)-１，３，５-트리아진-２,４-디아민 화합물
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
WO2016053850A1 (en) 2014-09-29 2016-04-07 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
JP7220986B6 (ja) 2015-02-04 2024-02-08 アジオス ファーマシューティカルズ， インコーポレイテッド 治療効果のある化合物及びその使用方法
EP3331866B1 (en) 2015-08-05 2023-07-26 Les Laboratoires Servier Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine
CN108366980A (zh) 2015-10-15 2018-08-03 安吉奥斯医药品有限公司 用于治疗恶性肿瘤的组合疗法
IL298663A (en) 2015-12-04 2023-01-01 Agios Pharmaceuticals Inc Methods of treatment of acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras
US20190046512A1 (en) 2016-02-26 2019-02-14 Agios Pharmaceuticals, Inc. Idh1 inhibitors for the treatment of haematological malgnancies and solid tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017821A2 (en) * 2013-08-02 2015-02-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
MX381582B (es) 2025-03-12
EP3362070B1 (en) 2021-01-27
ES2862730T3 (es) 2021-10-07
IL258580A (en) 2018-05-31
CL2018000955A1 (es) 2018-09-14
CA3002029A1 (en) 2017-04-20
SG11201802964QA (en) 2018-05-30
WO2017066611A1 (en) 2017-04-20
IL258580B (en) 2021-05-31
SG10201912869WA (en) 2020-02-27
NZ741433A (en) 2024-07-26
JP6895956B2 (ja) 2021-06-30
BR112018007447B1 (pt) 2023-12-05
US20210100805A1 (en) 2021-04-08
JP2018535951A (ja) 2018-12-06
US20180303840A1 (en) 2018-10-25
MX2018004599A (es) 2018-09-21
EA036129B1 (ru) 2020-10-01
CN108601787A (zh) 2018-09-28
KR102701893B1 (ko) 2024-09-03
US10695352B2 (en) 2020-06-30
EP3362070A1 (en) 2018-08-22
EA201890961A1 (ru) 2018-11-30
CN108601787B (zh) 2022-07-29
ZA201802420B (en) 2020-08-26
BR112018007447A2 (en) 2018-10-23
AU2016340098A1 (en) 2018-05-10
KR20180064529A (ko) 2018-06-14

Similar Documents

Publication Publication Date Title
AU2016340098B2 (en) Combination therapy for treating malignancies
EP3419593B1 (en) Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia
EP3383400B1 (en) Methods of treatment of malignancies
AU2016338557B2 (en) Combination therapy for treating malignancies
US10905692B2 (en) Combination therapy for treating malignancies
EP3493809B1 (en) Enasidenib for treatment of myelodysplastic syndrome

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CELGENE CORPORATION

Free format text: FORMER APPLICANT(S): AGIOS PHARMACEUTICALS, INC.; CELGENE CORPORATION

Owner name: LES LABORATORIES SERVIER

Free format text: FORMER APPLICANT(S): AGIOS PHARMACEUTICALS, INC.; CELGENE CORPORATION

TH Corrigenda

Free format text: IN VOL 36 , NO 20 , PAGE(S) 2696 UNDER THE HEADING ASSIGNMENTS BEFORE GRANT, SECTION 113 - 2016 UNDER THE NAME LES LABORATORIES SERVIER AND CELGENE CORPORATION. APPLICATION NO. 2016340098, UNDER INID (71) CORRECT THE CO-APPLICANT TO LES LABORATOIRES SERVIER

FGA Letters patent sealed or granted (standard patent)